In silico preselection of fungicide potentiator candidates
An innovative approach leveraging in silico prescreening to identify fungicide potentiators that target resistance mechanisms, enhancing fungicide efficacy. This method aims to increase efficiency and synergy by focusing on strategic compound selection, minimizing resources.
Overview
Our technology offers a novel method for identifying fungicide potentiators that enhance the efficacy of existing fungicides by targeting specific fungal resistance mechanisms. By employing in silico prescreening, we strategically select compounds that are most likely to disrupt resistance pathways, such as efflux pumps or detoxification enzymes. This approach increases the likelihood of achieving synergistic effects and reduces inefficiencies associated with broad-spectrum screening.
Technical specifications
- Targeted resistance mechanisms: Focuses on efflux pumps and detoxification enzymes to restore or boost fungicide activity.
- Rational compound selection: Utilizes mechanistic insights to select compounds based on their potential to disrupt resistance mechanisms.
- In silico prescreening: Prioritizes candidates early in the research process, reducing the need for extensive lab resources.
- Validation methods: Includes in vitro confirmation through targeted assays, such as vesicle assays for efflux transport, and checkerboard assays to identify potentiator profiles.
Technology readiness level
Currently at Technology Readiness Level 3, this technology has been validated through in silico prescreening and is moving towards in vitro confirmation and upscaled production phases.
About BioNotus
BioNotus is a GLP-certified contract research organization based in Niel, Belgium, that specializes in providing integrated solutions for drug discovery and development. Founded in 2017, the company offers a unique, combined portfolio of services encompassing bioanalysis, pharmacometrics, and discovery ADMET profiling. Its laboratory is equipped for LC-MS/MS-based bioanalysis to quantify drugs, metabolites, and biomarkers in diverse biological matrices, while its pharmacometrics division utilizes computational modeling and simulation, including population and physiology-based pharmacokinetic (PBPK) approaches, to guide clinical study design and dosing strategies. By offering both laboratory and consulting capabilities under one roof, BioNotus aims to enhance project efficiency and data-driven decision-making for its clients.
The company serves a wide range of partners, including university hospitals, academic researchers, and small-to-medium-sized pharmaceutical and biotech firms. By converting complex experimental data into actionable insights, BioNotus helps clients navigate regulatory requirements, optimize dosing in special populations, and improve the success rates of preclinical and clinical trials. Their approach emphasizes fit-for-purpose solutions and iterative integration of bioanalytical data with predictive modeling, providing customers with affordable, high-quality support that spans the entire lifecycle of drug development from early discovery stages to late-stage clinical evaluation.
Inquire about this partnering listing
Industry applications
delivered to your inbox.